Sudhinder Koushik, MD
Ophthalmology · San Jose
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Koushik’s office at (408) 984-1010 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$3,321
Medicare paid this office $3,321 for 25 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
25 Original Medicare patients in 2024. Average age 76 · Under 65 0% · Also on Medicaid 0% · Health risk score 0.86. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75%.
The office billed $7,774, Medicare allowed $4,404 and paid $3,321; for 36 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 25 | 36 | 76 | 0.86 | $7,774 | $3,321 |
| 2023 | 23 | 30 | 76 | 0.81 | $4,528 | $2,076 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Drugs they prescribed that Part D paid
$4,527
Pharmacies billed $4,527 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 55) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
36 generic and 19 brand-name prescriptions · $4,527 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Latanoprost | 11 | $36 | $3 |
Year by year
| 2024 | 55 | 28 | 0% (0) | 35% | $4,527 |
| 2023 | 202 | 75 | 0% (0) | 57% | $15,780 |
| 2022 | 197 | 83 | None | 34% | $9,379 |
| 2021 | 259 | 105 | 0% (0) | 63% | $17,285 |
| 2020 | 131 | 67 | 0% (0) | 73% | $7,524 |
| 2019 | 20 | 12 | None | None | $1,767 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Moxifloxacin | 39 | $1,354 | $35 |
| Prednisolone Acetate | 37 | $1,244 | $34 |
| Latanoprost | 24 | $274 | $11 |
| Dorzolamide | 21 | $143 | $7 |
| Brimonidine | 11 | $119 | $11 |
2022: 5 drugs
| Prednisolone Acetate | 26 | $976 | $38 |
| Neomycin-Polymyxin-Dexameth | 33 | $726 | $22 |
| Moxifloxacin | 34 | $531 | $16 |
| Erythromycin | 32 | $338 | $11 |
| Latanoprost | 14 | $252 | $18 |
2021: 5 drugs
| Rocklatan | 11 | $3,352 | $305 |
| Prednisolone Acetate | 78 | $3,073 | $39 |
| Moxifloxacin | 52 | $2,227 | $43 |
| Latanoprost | 45 | $716 | $16 |
| Dorzolamide-Timolol | 15 | $510 | $34 |
2020: 2 drugs
| Moxifloxacin | 61 | $3,027 | $50 |
| Prednisolone Acetate | 31 | $1,271 | $41 |
Money from drug and device companies
$120 in 2025
| 2025 | 1 | 1 | None | $120 |
| 2024 | 9 | 19 | None | $901 |
| 2023 | 5 | 19 | None | $1,860 |
| 2022 | 7 | 13 | None | $740 |
| 2021 | 4 | 6 | None | $344 |
| 2020 | 1 | 1 | None | $23 |
| 2019 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Carl Zeiss Meditec USA | None | $120 | 1 payment
|
See the published payment
| Carl Zeiss Meditec USA | Meals · 2025-07-10 | None | $120 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $901
| Carl Zeiss Meditec USA | Visumax | $433 | 3 payments
|
| Alcon Vision | Hydrus Microstent | $252 | 8 payments
|
| Dompe US | Oxervate | $57 | 2 payments
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $36 | 1 payment
|
| Carl Zeiss Meditec | None | $36 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $26 | 1 payment
|
| Sight Sciences | Omni Surgical System | $21 | 1 payment
|
| Harrow Eye | Vevye | $21 | 1 payment
|
| RxSight | Rxsight Injector Handpiece | $18 | 1 payment
|
2023: $1,860
| Alcon Vision | Hydrus Microstent | $1,288 | 9 payments
|
| Abbvie | Xen Glaucoma Treatment System | $415 | 5 payments
|
| Sun Pharmaceutical Industries | Cequa | $64 | 1 payment
|
| Carl Zeiss Meditec USA | Artevo 800 | $64 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $29 | 1 payment
|
2022: $740
| Sight Sciences | Omni(R) Surgical System (US) | $231 | 4 payments
|
| Bausch & Lomb Americas | Envista Mx60 Iol | $131 | 2 payments
|
| Alcon Vision | Clareon | $122 | 2 payments
|
| Genentech USA | Susvimo | $104 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $74 | 1 payment
|
| Abbvie | Durysta | $54 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $25 | 1 payment
|
2021: $344
| Sight Sciences | Omni(R) Surgical System (US) | $171 | 3 payments
|
| Allergan | Xen Glaucoma Treatment System | $84 | 1 payment
|
| New World Medical | Ahmed Glaucoma Valve | $75 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $14 | 1 payment
|
2020: $23
| Allergan | Durysta | $23 | 1 payment
|
2019: $20
| Horizon Therapeutics plc | Krystexxa | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1336700863
- Licence
- MO 2019021888, MO 2020013957
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Internal medicine (207R00000X)
- Mailing address
- 606 Saratoga Ave, San Jose, CA, 95129
- NPI first listed
- 2019-06-25
- NPI last updated
- 2026-07-07
- NPI record certified
- 2026-07-07
This is when the NPI record was last certified, not a medical board exam.